Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ODTX · Why this verdict
Why Odyssey Therapeutics (ODTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Odyssey Therapeutics is a pre-revenue biotech with widening losses and below-floor quality, offset by strong analyst upside, improving volume-led momentum and very positive news sentiment.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scores 3.0, below the 4.0 floor, with quarterly revenue at $0 in the last two reported quarters and zero margins, so the business has no operating revenue base. Quality breakdown | Quality stays below 4.0 until a collaboration or product generates revenue. | →Stable |
| CounterPre-revenue biotechs are valued on pipeline, so low quality scores may be irrelevant if clinical data prove positive. | ||
The analyst target of $30.74 sits 56.8% above the $19.60 price after a haircut, with raw analyst upside noted at 80%. Upside pct | Price moves toward the analyst target as clinical and financial milestones are met over 12 months. | →Stable |
| CounterCoverage is light (dampened signal) and biotech targets often depend on binary trial outcomes that can erase the upside overnight. | ||
Odyssey missed EPS estimates in both reported quarters: a loss of $1.27 versus an expected $0.85 loss and a loss of $6.75 versus an expected $1.28 loss. Earnings | Losses narrow toward consensus estimates as spending stabilizes over the next four quarters. | ↓Deteriorating |
| CounterLarge one-time charges may explain the $6.75 loss, and consensus loss estimates for clinical-stage biotechs are unreliable. | ||
Momentum scores 6.4 with rising OBV and a MACD component of 10, indicating accumulation even though RSI is a neutral 44. Momentum breakdown | Rising OBV continues and the momentum score holds above 5.5 over the next two quarters. | ↑Improving |
| CounterThe stock sits low in its 52-week range (position score 3.5) and volume component is only 2.1, so accumulation may be thin and easily reversed. | ||
LLM news sentiment is +0.85 on a sample of 2 articles, and the sentiment score is 8.8. Sentiment breakdown | News flow stays net positive as the company reports its next quarter in 12 days. | ↓Deteriorating |
| CounterA sample of only 2 articles is tiny, and positive headlines often precede disappointing trial or financing news. | ||
Quality scores 3.0, below the 4.0 floor, with quarterly revenue at $0 in the last two reported quarters and zero margins, so the business has no operating revenue base.
→StableQuality breakdown
- Expectation
- Quality stays below 4.0 until a collaboration or product generates revenue.
CounterPre-revenue biotechs are valued on pipeline, so low quality scores may be irrelevant if clinical data prove positive.
The analyst target of $30.74 sits 56.8% above the $19.60 price after a haircut, with raw analyst upside noted at 80%.
→StableUpside pct
- Expectation
- Price moves toward the analyst target as clinical and financial milestones are met over 12 months.
CounterCoverage is light (dampened signal) and biotech targets often depend on binary trial outcomes that can erase the upside overnight.
Odyssey missed EPS estimates in both reported quarters: a loss of $1.27 versus an expected $0.85 loss and a loss of $6.75 versus an expected $1.28 loss.
↓DeterioratingEarnings
- Expectation
- Losses narrow toward consensus estimates as spending stabilizes over the next four quarters.
CounterLarge one-time charges may explain the $6.75 loss, and consensus loss estimates for clinical-stage biotechs are unreliable.
Momentum scores 6.4 with rising OBV and a MACD component of 10, indicating accumulation even though RSI is a neutral 44.
↑ImprovingMomentum breakdown
- Expectation
- Rising OBV continues and the momentum score holds above 5.5 over the next two quarters.
CounterThe stock sits low in its 52-week range (position score 3.5) and volume component is only 2.1, so accumulation may be thin and easily reversed.
LLM news sentiment is +0.85 on a sample of 2 articles, and the sentiment score is 8.8.
↓DeterioratingSentiment breakdown
- Expectation
- News flow stays net positive as the company reports its next quarter in 12 days.
CounterA sample of only 2 articles is tiny, and positive headlines often precede disappointing trial or financing news.
Per-dimension breakdown
Quality
3.0/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 74%
Insider
5.0/10data confidence 50%Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 2.5 |
| 52w position | 4.0 |
Risk (lower is worse)
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 6.1 |
| days to cover | 2.2 |
| volatility | 0.0 |
| debt equity | 9.8 |
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/2M
- ▸Earnings in 7 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:3.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:7d<=7d
Warning (0)
none
Reward-to-Risk
3.44
Upside
+51.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 7d<=7d outcome against Value at 9.0 and asymmetric R:R of 3.44.
The strongest dimensions are Value at 9.0, Sentiment at 7.6, and Momentum at 6.0; the weakest are Catalyst at 2.5, Technical at 2.7, and Quality at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 3.44 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside
Trip ifAnalyst target falls below $22, under 12% above the current $19.60 price.
- P2Losses Worse Than Estimates
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters, disproving the pattern of larger-than-expected losses.
- P3No Revenue Quality Below Floor
Trip ifQuarterly revenue exceeds $5M, which would end the no-revenue profile.
- P4Volume Led Momentum
Trip ifMomentum score falls below 4.5 from current 6.4.
- P5Strongly Positive News Sentiment
Trip ifLLM news sentiment falls below 0.0 from current +0.85.